<ul>
<li>关注美联储降息后的三只小盘股</li>
</ul>
<p>Emergent Biosolutions（纽约证券交易所代码：EBS）于周二召开了 2026 年股东年会，股东们对董事选举、审计师确认、管理层薪酬以及增加公司股票激励计划可用股份的修正案进行了投票。管理层还回顾了 2025 年在其所称的多年度转型努力中取得的进展。</p>
<p>获取 <strong>Emergent Biosolutions</strong> 的提醒：</p>
<h2>管理层强调 2025 年转型进展</h2>
<p>董事会主席 Zsolt Harsanyi 博士表示，公司在 2025 年 “显著推进” 了其转型和变革计划，提到通过 “精简高效的商业模式、强劲的运营业绩、利润率改善和债务减少” 来增强 Emergent 的财务状况。他补充说，董事会和领导团队对公司能够通过 “推动长期增长和盈利能力” 来创造股东价值充满信心，同时继续其 “保护和拯救生命” 的使命。</p>
<ul>
<li>大幅反弹即将来临？关注三只分析师推荐的股票</li>
</ul>
<p>总裁兼首席执行官 Joe Papa 表示，Emergent 在 2025 年 “在执行我们的多年度转型优先事项方面取得了显著进展”，指出运营利润率改善、“强劲的调整后息税折旧摊销前利润为 2.05 亿美元”、现金流增加和债务杠杆减少。</p>
<p>Papa 表示，在通过 “战略性剥离和运营举措” 稳定业务后，公司在 2025 年进一步增强了财务状况，并继续推进其转型计划。</p>
<h2>2025 年财务和运营里程碑</h2>
<ul>
<li>随着市场轮动继续，关注这四只超买股票</li>
</ul>
<p>在他的发言中，Papa 概述了他归功于公司团队的几项成就，包括流动性改善和债务减少。他表示，Emergent：</p>
<ul>
<li>现金余额增加了 1 亿美元</li>
<li>债务减少了 1.1 亿美元</li>
<li>实现了 “强劲的收益和现金流”</li>
</ul>
<p>Papa 还表示，公司获得了 “多个医疗对策合同，以支持美国及国际的生物防御准备”。在公司的纳洛酮业务中，他表示 Emergent 通过收购 Kloxxado 鼻用喷雾剂（8 毫克）的商业权利扩大了其产品组合，并 “保持了 NARCAN 鼻用喷雾剂的市场领导地位”。Papa 还提到 Emergent“宣布与瑞士火箭公司达成投资协议”。</p>
<p>他说，公司在 “患者安全、质量和合规性” 的明确关注下，采取的行动使 Emergent 能够追求 “战略转型，以实现长期增长和盈利能力”。</p>
<h2>2026 年关注领域：管道、纳洛酮扩展和国际增长</h2>
<p>展望未来，Papa 表示，凭借更强的现金和流动性状况，Emergent 计划在其医疗对策和纳洛酮业务中投资于收入增长驱动因素。他表示，公司 2026 年的优先事项包括推进内部管道，推出旨在减少阿片类药物过量死亡的额外纳洛酮产品线扩展，以及加速国际增长。</p>
<p>Papa 还表示，Emergent 打算追求 “有针对性的收购和利用我们基础设施及能力的外部机会”。他补充说，他对 Emergent 成为 “解决全球社区公共卫生威胁的领导者” 的愿景保持乐观。</p>
<h2>股东批准所有提案；董事当选</h2>
<p>在会议期间，高级副总裁、总法律顾问和公司秘书 Jessica Perl 概述了议程上的四项提案：</p>
<ul>
<li>选举 Sujata Dayal、Dr. Zsolt Harsanyi、Joseph Papa 和 John D. Fowler, Jr.为二级董事，任期至 2029 年股东年会结束</li>
<li>确认 Ernst &amp; Young LLP 为截至 2026 年 12 月 31 日的财政年度独立注册公共会计师</li>
<li>对 2025 年指定高管的薪酬进行咨询投票</li>
<li>批准修正案以增加公司修订和重述的股票激励计划下可用于奖励的股份</li>
</ul>
<p>Harsanyi 随后宣布初步投票结果，表示每位董事提名人均获得 “投票的多数”，并当选。他表示，审计师确认提案和高管薪酬咨询投票以及股票激励计划股份增加修正案均获得 “多数投票”。</p>
<p>Harsanyi 表示，Emergent 预计将在会议后四个工作日内向证券交易委员会提交的 8-K 表格中报告最终投票结果。</p>
<h2>未提交股东提问</h2>
<p>在正式业务结束后，公司开启了问答环节。主持人表示没有收到任何问题，虚拟股东年会随即结束。</p>
<h2>关于 Emergent Biosolutions（纽约证券交易所代码：EBS）</h2>
<p>Emergent BioSolutions 是一家全球专注于开发、生产和商业化医疗对策及特殊产品的生物制药公司，旨在应对公共卫生威胁。公司的产品组合包括疫苗、抗体疗法和关键护理产品，旨在保护人们免受生物、化学和新兴传染病威胁。Emergent 与政府机构（包括美国国防部和生物医学先进研究与发展局（BARDA））建立了长期合作关系，以支持国家准备计划。</p>
<p>Emergent 产品线中的关键商业产品包括 BioThrax（炭疽疫苗吸附剂）、ACAM2000（天花疫苗）和 Vaxchora（霍乱疫苗），以及治疗性产品如 Anthrasil（炭疽免疫球蛋白）和用于阿片类药物过量逆转的纳洛酮鼻用喷雾剂 Narcan。</p>
<h2>了解更多</h2>
<ul>
<li>五只我们更看好的股票，胜过 Emergent Biosolutions</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1000 美元在 Emergent Biosolutions 吗？</h2>
<p>在考虑 Emergent Biosolutions 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Emergent Biosolutions 并不在名单上。</p>
<p>虽然 Emergent Biosolutions 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

动态生物技术与基因组 ETF - Invesco

IBBQ

纳斯达克生物科技指数 ETF - iShares Nasdaq

标普生物技术 3 倍做多 - Direxion

生物科技 ETF - VanEck Vectors

标普生物技术 ETF - SPDR

纽交所高增长板生物技术指数 ETF - First Trust

2 倍做多纳斯达克生物技术 ETF - ProShares

<p>Emergent BioSolutions 举行了 2026 年年度股东大会，股东们批准了所有提案，包括董事选举和增加股票激励计划股份的修订。管理层报告了其多年转型的显著进展，强调了财务指标的改善，如 2.05 亿美元的调整后 EBITDA 和减少的债务。公司计划在 2026 年专注于推进其产品管线、纳洛酮扩展和国际增长，同时也将追求战略收购。所有董事提名人均已当选，审计师也已获得批准，适用于截至 2026 年 12 月 31 日的财政年度</p>

<ul>
<li>3 Small-Cap Stocks to Watch After the Fed’s Rate Cuts</li>
</ul>
<div class="lb-trans"><ul>
<li>关注美联储降息后的三只小盘股</li>
</ul>
</div><p>Emergent Biosolutions NYSE: EBS on Tuesday held its 2026 Annual Meeting of Stockholders, where shareholders voted on director elections, auditor ratification, executive compensation, and an amendment to increase shares available under the company’s stock incentive plan. Management also reviewed progress made in 2025 as part of what it described as a multi-year turnaround effort.</p>
<div class="lb-trans"><p>Emergent Biosolutions（纽约证券交易所代码：EBS）于周二召开了 2026 年股东年会，股东们对董事选举、审计师确认、管理层薪酬以及增加公司股票激励计划可用股份的修正案进行了投票。管理层还回顾了 2025 年在其所称的多年度转型努力中取得的进展。</p>
</div><p>Get <strong>Emergent Biosolutions</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Emergent Biosolutions</strong> 的提醒：</p>
</div><h2>Management highlights 2025 turnaround progress</h2>
<div class="lb-trans"><h2>管理层强调 2025 年转型进展</h2>
</div><p>Board Chair Dr. Zsolt Harsanyi said the company “significantly progressed” its turnaround and transformation plan in 2025, citing efforts to strengthen Emergent’s financial position through “a lean and efficient business model, strong operating results, margin improvements, and debt reduction.” He added that the board and leadership team remain confident the company can create shareholder value by “driving long-term growth and profitability” while continuing its mission to “protect and save lives.”</p>
<div class="lb-trans"><p>董事会主席 Zsolt Harsanyi 博士表示，公司在 2025 年 “显著推进” 了其转型和变革计划，提到通过 “精简高效的商业模式、强劲的运营业绩、利润率改善和债务减少” 来增强 Emergent 的财务状况。他补充说，董事会和领导团队对公司能够通过 “推动长期增长和盈利能力” 来创造股东价值充满信心，同时继续其 “保护和拯救生命” 的使命。</p>
</div><ul>
<li>Big Rallies Brewing? 3 Analyst Favorites to Watch Closely</li>
</ul>
<div class="lb-trans"><ul>
<li>大幅反弹即将来临？关注三只分析师推荐的股票</li>
</ul>
</div><p>President and CEO Joe Papa said Emergent made “significant progress executing our multi-year turnaround priorities” during 2025, pointing to improved operating margins, “strong adjusted EBITDA of $205 million,” increased cash flow, and reduced debt leverage.</p>
<div class="lb-trans"><p>总裁兼首席执行官 Joe Papa 表示，Emergent 在 2025 年 “在执行我们的多年度转型优先事项方面取得了显著进展”，指出运营利润率改善、“强劲的调整后息税折旧摊销前利润为 2.05 亿美元”、现金流增加和债务杠杆减少。</p>
</div><p>Papa said that after stabilizing the business through “strategic divestitures and operational initiatives,” the company further strengthened its financial position in 2025 and continued advancing its turnaround plan.</p>
<div class="lb-trans"><p>Papa 表示，在通过 “战略性剥离和运营举措” 稳定业务后，公司在 2025 年进一步增强了财务状况，并继续推进其转型计划。</p>
</div><h2>Financial and operational milestones cited for 2025</h2>
<div class="lb-trans"><h2>2025 年财务和运营里程碑</h2>
</div><ul>
<li>Watch These 4 Overbought Stocks As Market Rotation Continues</li>
</ul>
<div class="lb-trans"><ul>
<li>随着市场轮动继续，关注这四只超买股票</li>
</ul>
</div><p>In his remarks, Papa outlined several accomplishments he attributed to the company’s team, including improved liquidity and debt reduction. He said Emergent:</p>
<div class="lb-trans"><p>在他的发言中，Papa 概述了他归功于公司团队的几项成就，包括流动性改善和债务减少。他表示，Emergent：</p>
</div><ul>
<li>Improved its cash balance by $100 million</li>
<li>Reduced debt by $110 million</li>
<li>Delivered “strong earnings and cash flow”</li>
</ul>
<div class="lb-trans"><ul>
<li>现金余额增加了 1 亿美元</li>
<li>债务减少了 1.1 亿美元</li>
<li>实现了 “强劲的收益和现金流”</li>
</ul>
</div><p>Papa also said the company secured “multiple medical countermeasures contract awards for biodefense preparedness in the U.S. and internationally.” In the company’s naloxone business, he said Emergent expanded its portfolio by acquiring the commercial rights to Kloxxado nasal spray (8 mg) and “maintained market leadership for NARCAN nasal spray.” Papa also noted Emergent “announced an investment agreement with Swiss Rockets.”</p>
<div class="lb-trans"><p>Papa 还表示，公司获得了 “多个医疗对策合同，以支持美国及国际的生物防御准备”。在公司的纳洛酮业务中，他表示 Emergent 通过收购 Kloxxado 鼻用喷雾剂（8 毫克）的商业权利扩大了其产品组合，并 “保持了 NARCAN 鼻用喷雾剂的市场领导地位”。Papa 还提到 Emergent“宣布与瑞士火箭公司达成投资协议”。</p>
</div><p>He said the company’s actions, alongside its stated focus on “patient safety, quality, and compliance,” position Emergent to pursue “strategic transformation for long-term growth and profitability.”</p>
<div class="lb-trans"><p>他说，公司在 “患者安全、质量和合规性” 的明确关注下，采取的行动使 Emergent 能够追求 “战略转型，以实现长期增长和盈利能力”。</p>
</div><h2>2026 focus areas: pipeline, naloxone extensions, and international growth</h2>
<div class="lb-trans"><h2>2026 年关注领域：管道、纳洛酮扩展和国际增长</h2>
</div><p>Looking ahead, Papa said that with a stronger cash and liquidity position, Emergent plans to invest in revenue growth drivers across its medical countermeasures and naloxone businesses. He said the company’s 2026 priorities include advancing its internal pipeline, launching additional naloxone line extensions aimed at reducing opioid overdose deaths, and accelerating international growth.</p>
<div class="lb-trans"><p>展望未来，Papa 表示，凭借更强的现金和流动性状况，Emergent 计划在其医疗对策和纳洛酮业务中投资于收入增长驱动因素。他表示，公司 2026 年的优先事项包括推进内部管道，推出旨在减少阿片类药物过量死亡的额外纳洛酮产品线扩展，以及加速国际增长。</p>
</div><p>Papa also said Emergent intends to pursue “targeted acquisitions and external opportunities that leverage our infrastructure and capabilities.” He added that he remains optimistic about Emergent’s vision to be “the leader in solving public health threats for communities around the world.”</p>
<div class="lb-trans"><p>Papa 还表示，Emergent 打算追求 “有针对性的收购和利用我们基础设施及能力的外部机会”。他补充说，他对 Emergent 成为 “解决全球社区公共卫生威胁的领导者” 的愿景保持乐观。</p>
</div><h2>Shareholders approve all proposals; directors elected</h2>
<div class="lb-trans"><h2>股东批准所有提案；董事当选</h2>
</div><p>During the meeting, Senior Vice President, General Counsel, and Corporate Secretary Jessica Perl outlined four proposals on the agenda:</p>
<div class="lb-trans"><p>在会议期间，高级副总裁、总法律顾问和公司秘书 Jessica Perl 概述了议程上的四项提案：</p>
</div><ul>
<li>Election of Sujata Dayal, Dr. Zsolt Harsanyi, Joseph Papa, and John D. Fowler, Jr. as Class II directors for terms expiring at the 2029 Annual Meeting of Stockholders</li>
<li>Ratification of Ernst &amp; Young LLP as independent registered public accounting firm for the fiscal year ending Dec. 31, 2026</li>
<li>Advisory vote to approve the 2025 compensation of named executive officers</li>
<li>Approval of an amendment to increase shares available for awards under the company’s Amended and Restated Stock Incentive Plan</li>
</ul>
<div class="lb-trans"><ul>
<li>选举 Sujata Dayal、Dr. Zsolt Harsanyi、Joseph Papa 和 John D. Fowler, Jr.为二级董事，任期至 2029 年股东年会结束</li>
<li>确认 Ernst &amp; Young LLP 为截至 2026 年 12 月 31 日的财政年度独立注册公共会计师</li>
<li>对 2025 年指定高管的薪酬进行咨询投票</li>
<li>批准修正案以增加公司修订和重述的股票激励计划下可用于奖励的股份</li>
</ul>
</div><p>Harsanyi later announced preliminary voting results, stating each director nominee received “a plurality of the votes cast” and was elected. He said the auditor ratification proposal received “a majority of the votes cast,” as did the advisory vote on executive compensation and the stock incentive plan share increase amendment.</p>
<div class="lb-trans"><p>Harsanyi 随后宣布初步投票结果，表示每位董事提名人均获得 “投票的多数”，并当选。他表示，审计师确认提案和高管薪酬咨询投票以及股票激励计划股份增加修正案均获得 “多数投票”。</p>
</div><p>Harsanyi said Emergent expects to report final voting results in a Form 8-K filed with the Securities and Exchange Commission within four business days of the meeting.</p>
<div class="lb-trans"><p>Harsanyi 表示，Emergent 预计将在会议后四个工作日内向证券交易委员会提交的 8-K 表格中报告最终投票结果。</p>
</div><h2>No shareholder questions submitted</h2>
<div class="lb-trans"><h2>未提交股东提问</h2>
</div><p>After the formal business concluded, the company opened a question-and-answer portion of the meeting. The operator said no questions were received, and the virtual annual meeting was then concluded.</p>
<div class="lb-trans"><p>在正式业务结束后，公司开启了问答环节。主持人表示没有收到任何问题，虚拟股东年会随即结束。</p>
</div><h2>About Emergent Biosolutions NYSE: EBS</h2>
<div class="lb-trans"><h2>关于 Emergent Biosolutions（纽约证券交易所代码：EBS）</h2>
</div><p>Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company's portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.</p>
<div class="lb-trans"><p>Emergent BioSolutions 是一家全球专注于开发、生产和商业化医疗对策及特殊产品的生物制药公司，旨在应对公共卫生威胁。公司的产品组合包括疫苗、抗体疗法和关键护理产品，旨在保护人们免受生物、化学和新兴传染病威胁。Emergent 与政府机构（包括美国国防部和生物医学先进研究与发展局（BARDA））建立了长期合作关系，以支持国家准备计划。</p>
</div><p>Key commercial products in Emergent's lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.</p>
<div class="lb-trans"><p>Emergent 产品线中的关键商业产品包括 BioThrax（炭疽疫苗吸附剂）、ACAM2000（天花疫苗）和 Vaxchora（霍乱疫苗），以及治疗性产品如 Anthrasil（炭疽免疫球蛋白）和用于阿片类药物过量逆转的纳洛酮鼻用喷雾剂 Narcan。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Emergent Biosolutions</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Emergent Biosolutions</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Emergent Biosolutions Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Emergent Biosolutions 吗？</h2>
</div><p>Before you consider Emergent Biosolutions, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Emergent Biosolutions 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Emergent Biosolutions wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Emergent Biosolutions 并不在名单上。</p>
</div><p>While Emergent Biosolutions currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Emergent Biosolutions 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Emergent BioSolutions Shares Turnaround Update at 2026 Annual Meeting; All Proposals Approved

Market Beat

Emergent Biosolutions

Invesco Nasdaq Biotechnology ETF

Emergent BioSolutions 在 2026 年年度会议上提供了转型更新；所有提案均已获批